

**American
National
Standard**

ANSI/AAMI/ISO 10993-1:2003

**Biological evaluation
of medical devices—
Part 1: Evaluation and testing**

The Objectives and Uses of AAMI Standards and Recommended Practices

It is most important that the objectives and potential uses of an AAMI product standard or recommended practice are clearly understood. The objectives of AAMI's technical development program derive from AAMI's overall mission: the advancement of medical instrumentation. Essential to such advancement are (1) a continued increase in the safe and effective application of current technologies to patient care, and (2) the encouragement of new technologies. It is AAMI's view that standards and recommended practices can contribute significantly to the advancement of medical instrumentation, provided that they are drafted with attention to these objectives and provided that arbitrary and restrictive uses are avoided.

A voluntary *standard* for a *medical device* recommends to the manufacturer the information that should be provided with or on the product, basic safety and performance criteria that should be considered in qualifying the device for clinical use, and the measurement techniques that can be used to determine whether the device conforms with the safety and performance criteria and/or to compare the performance characteristics of different products. Some standards emphasize the information that should be provided with the device, including performance characteristics, instructions for use, warnings and precautions, and other data considered important in ensuring the safe and effective use of the device in the clinical environment. Recommending the disclosure of performance characteristics often necessitates the development of specialized test methods to facilitate uniformity in reporting; reaching consensus on these tests can represent a considerable part of committee work. When a drafting committee determines that clinical concerns warrant the establishment of *minimum* safety and performance criteria, referee tests must be provided and the reasons for establishing the criteria must be documented in the rationale.

A *recommended practice* provides guidelines for the use, care, and/or processing of a medical device or system. A recommended practice does not address device performance *per se*, but rather procedures and practices that will help ensure that a device is used safely and effectively and that its performance will be maintained.

Although a device standard is primarily directed to the manufacturer, it may also be of value to the potential purchaser or user of the device as a fume of reference for device evaluation. Similarly, even though a recommended practice is usually oriented towards health care professionals, it may be useful to the manufacturer in better understanding the environment in which a medical device will be used. Also, some recommended practices, while not addressing device performance criteria, provide guidelines to industrial personnel on such subjects as sterilization processing, methods of collecting data to establish safety and efficacy, human engineering, and other processing or evaluation techniques; such guidelines may be useful to health care professionals in understanding industrial practices.

In determining whether an AAMI standard or recommended practice is relevant to the specific needs of a potential user of the document, several important concepts must be recognized:

All AAMI standards and recommended practices are *voluntary* (unless, of course, they are adopted by government regulatory or procurement authorities). The application of a standard or recommended practice is solely within the discretion and professional judgment of the user of the document.

Each AAMI standard or recommended practice reflects the collective expertise of a committee of health care professionals and industrial representatives, whose work has been reviewed nationally (and sometimes internationally). As such, the consensus recommendations embodied in a standard or recommended practice are intended to respond to clinical needs and, ultimately, to help ensure patient safety. A standard or recommended practice is limited, however, in the sense that it responds generally to perceived risks and conditions that may not always be relevant to specific situations. A standard or recommended practice is an important *reference* in responsible decision-making, but it should never *replace* responsible decisionmaking.

Despite periodic review and revision (at least once every five years), a standard or recommended practice is necessarily a static document applied to a dynamic technology. Therefore, a standards user must carefully review the reasons why the document was initially developed and the specific rationale for each of its provisions. This review will reveal whether the document remains relevant to the specific needs of the user.

Particular care should be taken in applying a product standard to existing devices and equipment, and in applying a recommended practice to current procedures and practices. While observed or potential risks with existing equipment typically form the basis for the safety and performance criteria defined in a standard, professional judgment must be used in applying these criteria to existing equipment. No single source of information will serve to identify a particular product as "unsafe". A voluntary standard can be used as one resource, but the ultimate decision as to product safety and efficacy must take into account the specifics of its utilization and, of course, cost-benefit considerations. Similarly, a recommended practice should be analyzed in the context of the specific needs and resources of the individual institution or firm. Again, the rationale accompanying each AAMI standard and recommended practice is an excellent guide to the reasoning and data underlying its provision.

In summary, a standard or recommended practice is truly useful only when it is used in conjunction with other sources of information and policy guidance and in the context of professional experience and judgment.

INTERPRETATIONS OF AAMI STANDARDS AND RECOMMENDED PRACTICES

Requests for interpretations of AAMI standards and recommended practices must be made in writing, to the Manager for Technical Development. An official interpretation must be approved by letter ballot of the originating committee and subsequently reviewed and approved by the AAMI Standards Board. The interpretation will become official and representation of the Association only upon exhaustion of any appeals and upon publication of notice of interpretation in the "Standards Monitor" section of the *AAMI News*. The Association for the Advancement of Medical Instrumentation disclaims responsibility for any characterization or explanation of a standard or recommended practice which has not been developed and communicated in accordance with this procedure and which is not published, by appropriate notice, as an *official interpretation* in the *AAMI News*.

Biological evaluation of medical devices— Part 1: Evaluation and testing

Approved 8 October 2003 by
Association for the Advancement of Medical Instrumentation

Approved 23 October 2003 by
American National Standards Institute

Abstract: Describes the general principles governing the biological evaluation of medical devices, the categorization of devices based on the nature and duration of their contact with the body, and the selection of appropriate tests.

Keywords: biological evaluation, medical device

AAMI Standard

This Association for the Advancement of Medical Instrumentation (AAMI) standard implies a consensus of those substantially concerned with its scope and provisions. The existence of an AAMI standard does not in any respect preclude anyone, whether they have approved the standard or not, from manufacturing, marketing, purchasing, or using products, processes, or procedures not conforming to the standard. AAMI standards are subject to periodic review, and users are cautioned to obtain the latest editions.

CAUTION NOTICE: This AAMI standard may be revised or withdrawn at any time. AAMI procedures require that action be taken to reaffirm, revise, or withdraw this standard no later than 5 years from the date of publication. Interested parties may obtain current information on all AAMI standards by calling or writing AAMI.

All AAMI standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Published by

Association for the Advancement of Medical Instrumentation
1110 N. Glebe Road, Suite 220
Arlington, VA 22201-4795

© 2003 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of ISO, ANSI, and AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this draft should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI, 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795. Phone: (703) 525-4890; Fax: (703) 525-1067.

Printed in the United States of America

ISBN 1-57020-206-0

Contents

	Page
Glossary of equivalent standards	v
Committee representation	vii
Background of ANSI/AAMI adoption of ISO 10993-1:2003	ix
Foreword	x
Introduction	xi
1 Scope.....	1
2 Terms and definitions.....	1
3 General principles applying to biological evaluation of medical devices.....	1
4 Categorization of medical devices.....	2
4.1 General	2
4.2 Categorization by nature of body contact	3
4.2.1 Non-contact devices	3
4.2.2 Surface-contacting devices.....	3
4.2.3 External communicating devices.....	3
4.2.4 Implant devices	3
4.3 Categorization by duration of contact	3
5 Testing	4
5.1 General	4
5.2 Initial evaluation tests	4
5.2.1 General	4
5.2.2 Cytotoxicity.....	4
5.2.3 Sensitization	4
5.2.4 Irritation.....	5
5.2.5 Intracutaneous reactivity	5
5.2.6 Systemic toxicity (acute toxicity)	5
5.2.7 Subacute and subchronic toxicity.....	5
5.2.8 Genotoxicity	5
5.2.9 Implantation	5
5.2.10 Hemocompatibility.....	5
5.3 Supplementary evaluation tests	6
5.3.1 General	6
5.3.2 Chronic toxicity.....	6
5.3.3 Carcinogenicity	6
5.3.4 Reproductive and developmental toxicity.....	6
5.3.5 Biodegradation.....	6
6 Selection of biological evaluation tests.....	6
7 Assurance of test methods.....	6
7.1 Test method assurance.....	6
7.2 Continued assurance	6

Annexes

A	Rationale	9
B	Flow chart to aid in ensuring a systemic approach to biological evaluation of medical devices	10
	Bibliography	11

Tables

1	Initial evaluation tests for consideration	7
2	Supplementary evaluation tests for consideration	8

Figure

B.1	Flow chart to aid in ensuring a systemic approach to biological evaluation of medical devices	10
------------	---	----

Glossary of equivalent standards

International Standards adopted in the United States may include normative references to other International Standards. For each International Standard that has been adopted by AAMI (and ANSI), the table below gives the corresponding U.S. designation and level of equivalency to the International Standard.

NOTE—Documents are sorted by international designation.

Other normatively referenced International Standards may be under consideration for U.S. adoption by AAMI; therefore, this list should not be considered exhaustive.

International designation	U.S. designation	Equivalency
IEC 60601-1-2:2001	ANSI/AAMI/IEC 60601-1-2:2001	Identical
IEC 60601-2-21:1994 and Amendment 1:1996	ANSI/AAMI/IEC 60601-2-21 and Amendment 1:2000 (consolidated texts)	Identical
IEC 60601-2-24:1998	ANSI/AAMI ID26:1998	Major technical variations
ISO 5840:1996	ANSI/AAMI/ISO 5840:1996	Identical
ISO 7198:1998	ANSI/AAMI/ISO 7198:1998/2001	Identical
ISO 7199:1996	ANSI/AAMI/ISO 7199:1996/(R)2002	Identical
ISO 10993-1:2003	ANSI/AAMI/ISO 10993-1:2003	Identical
ISO 10993-2:1992	ANSI/AAMI/ISO 10993-2:1993/(R)2001	Identical
ISO 10993-3:2003	ANSI/AAMI/ISO 10993-3:2003	Identical
ISO 10993-4:2002	ANSI/AAMI/ISO 10993-4:2002	Identical
ISO 10993-5:1999	ANSI/AAMI/ISO 10993-5:1999	Identical
ISO 10993-6:1994	ANSI/AAMI/ISO 10993-6:1995/(R)2001	Identical
ISO 10993-7:1995	ANSI/AAMI/ISO 10993-7:1995/(R)2001	Identical
ISO 10993-8:2000	ANSI/AAMI/ISO 10993-8:2000	Identical
ISO 10993-9:1999	ANSI/AAMI/ISO 10993-9:1999	Identical
ISO 10993-10:2002	ANSI/AAMI BE78:2002	Minor technical variations
ISO 10993-11:1993	ANSI/AAMI 10993-11:1993	Minor technical variations
ISO 10993-12:2002	ANSI/AAMI/ISO 10993-12:2002	Identical
ISO 10993-13:1998	ANSI/AAMI/ISO 10993-13:1999	Identical
ISO 10993-14:2001	ANSI/AAMI/ISO 10993-14:2001	Identical
ISO 10993-15:2000	ANSI/AAMI/ISO 10993-15:2000	Identical
ISO 10993-16:1997	ANSI/AAMI/ISO 10993-16:1997/(R)2003	Identical
ISO 10993-17:2002	ANSI/AAMI/ISO 10993-17:2002	Identical
ISO 11134:1994	ANSI/AAMI/ISO 11134:1993	Identical
ISO 11135:1994	ANSI/AAMI/ISO 11135:1994	Identical
ISO 11137:1995 and Amendment 1:2001	ANSI/AAMI/ISO 11137:1994 and A1:2002	Identical
ISO 11138-1:1994	ANSI/AAMI ST59:1999	Major technical variations
ISO 11138-2:1994	ANSI/AAMI ST21:1999	Major technical variations

International designation	U.S. designation	Equivalency
ISO 11138-3:1995	ANSI/AAMI ST19:1999	Major technical variations
ISO TS 11139:2001	ANSI/AAMI/ISO 11139:2002	Identical
ISO 11140-1:1995 and Technical Corrigendum 1:1998	ANSI/AAMI ST60:1996	Major technical variations
ISO 11607:2003	ANSI/AAMI/ISO 11607:2000	Identical
ISO 11737-1:1995	ANSI/AAMI/ISO 11737-1:1995	Identical
ISO 11737-2:1998	ANSI/AAMI/ISO 11737-2:1998	Identical
ISO TR 13409:1996	AAMI/ISO TIR 13409:1996	Identical
ISO 13485:1996	ANSI/AAMI/ISO 13485:1996	Identical
ISO 13488:1996	ANSI/AAMI/ISO 13488:1996	Identical
ISO 14155-1:2003	ANSI/AAMI/ISO 14155-1:2003	Identical
ISO 14155-2:2003	ANSI/AAMI/ISO 14155-2:2003	Identical
ISO 14160:1998	ANSI/AAMI/ISO 14160:1998	Identical
ISO 14161:2000	ANSI/AAMI/ISO 14161:2000	Identical
ISO 14937:2000	ANSI/AAMI/ISO 14937:2000	Identical
ISO 14969:1999	ANSI/AAMI/ISO 14969:1999	Identical
ISO 14971:2000	ANSI/AAMI/ISO 14971:2000	Identical
ISO 15223:2000	ANSI/AAMI/ISO 15223:2000	Identical
ISO 15223/A1:2002	ANSI/AAMI/ISO 15223:2000/A1:2001	Identical
ISO 15225:2000	ANSI/AAMI/ISO 15225:2000	Identical
ISO 15674:2001	ANSI/AAMI/ISO 15674:2001	Identical
ISO 15675:2001	ANSI/AAMI/ISO 15675:2001	Identical
ISO 25539-1:2003	ANSI/AAMI/ISO 25539-1:2003	Identical
ISO TS 15843:2000	ANSI/AAMI/ISO TIR 15843:2000	Identical
ISO TR 15844:1998	AAMI/ISO TIR 15844:1998	Identical
ISO TR 16142:1999	ANSI/AAMI/ISO TIR 16142:2000	Identical

Committee representation

Association for the Advancement of Medical Instrumentation

Biological Evaluation Committee

The adoption of ISO 10993-1:2003 as an American National Standard was initiated by the AAMI Biological Evaluation Committee, which also functions as a U.S. Technical Advisory Group (TAG) to the relevant work in the International Organization for Standardization (ISO). U.S. representatives from the AAMI Systematic Approach to Biological Evaluation Working Group (U.S. Sub-TAG for ISO/TC 194/WG 1), chaired by James M. Anderson, MD, PhD, of Case Western Reserve University and Anita Y. Sawyer of Becton Dickinson & Company, played an active part in developing the ISO standard.

At the time this document was published, the **AAMI Biological Evaluation Committee** had the following members:

<i>Cochairs:</i>	Donald E. Marlowe Peter W. Urbanski
<i>Members:</i>	James M. Anderson, MD, PhD, Case Western Reserve University Roger Dabbah, PhD, U.S. Pharmacopeial Convention, Inc. Lawrence H. Hecker, PhD, Abbott Laboratories Edward Mueller, MS, Annapolis, MD Barry F.J. Page, Garner, NC Anita Y. Sawyer, Becton Dickinson & Company Melvin E. Stratmeyer, PhD, U.S. Food and Drug Administration/Center for Devices and Radiological Health/OST Paul J. Upman, PhD, NAMSA Peter W. Urbanski, Medtronic, Inc.
<i>Alternates:</i>	Raju G. Kammula, DVM, PhD, U.S. Food and Drug Administration/Center for Devices and Radiological Health/ODE Donald E. Marlowe, U.S. Food and Drug Administration/Center for Devices and Radiological Health Sharon J. Northup, PhD, U.S. Pharmacopeial Convention, Inc.

At the time this document was published, the **AAMI Systematic Approach to Biological Evaluation Working Group** had the following members:

<i>Cochairs:</i>	James M. Anderson, MD, PhD Anita Y. Sawyer
<i>Members:</i>	James M. Anderson, MD, PhD, Case Western Reserve University Michael M. Ball, TYCO Healthcare/Kendall Carolyn Braithwaite, Cobe Sterilization Services, Inc. Roger Dabbah, PhD, U.S. Pharmacopeial Convention, Inc. John Dooley, PhD, DABT, Johnson & Johnson Gloria H. Frost, PhD, Cardinal Health Medical Products and Services Group Lawrence H. Hecker, PhD, Abbott Laboratories Thomas Herbst, PhD, AppTec Laboratory Services Raju G. Kammula, DVM, PhD, U.S. Food and Drug Administration/Center for Devices and Radiological Health Anita Kore, DVM, PhD, 3M Healthcare Jack Lemons, PhD, Society for Biomaterials Jeff Nelson, BS, RM, Nelson Laboratories, Inc. Edward Reverdy, PhD, Boston Scientific Corporation Anita Y. Sawyer, Becton Dickinson & Company Brenda Seidman, PhD, Falls Church, VA Kenneth R. St. John, PhD, Jackson, MS Nancy J. Stark, PhD, Clinical Device Group, Inc. Paul J. Upman, PhD, NAMSA Peter W. Urbanski, Medtronic, Inc. Sherrie Wheelwright, Fresenius Medical Care NA Dialysis Products Division Randy D. White, PhD, Baxter Healthcare Corporation
<i>Alternates:</i>	Thomas J. Berger, PhD, Abbott Laboratories Jon Cammack, PhD, DABT, Baxter Healthcare Corporation Lee Ellis, Boston Scientific Corporation Joel R. Gorski, PhD, NAMSA

Amy Karren, Nelson Laboratories, Inc.
Sharon J. Northup, PhD, U.S. Pharmacopeial Convention, Inc.
Melvin E. Stratmeyer, PhD, U.S. Food and Drug Administration/Center for Devices and
Radiological Health

NOTE—Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any of its agencies.

Background of ANSI/AAMI adoption of ISO 10993-1:2003

As indicated in the foreword to the main body of this document (page x), the International Organization for Standardization (ISO) is a worldwide federation of national standards bodies. The United States is one of the ISO members that took an active role in the development of this standard.

International Standard ISO 10993-1 was developed by Technical Committee ISO/TC 194, *Biological evaluation of medical devices*, to provide general principles governing the biological evaluation of medical devices, the categorization of devices based on the nature and duration of their contact with the body, and the selection of appropriate tests.

U.S. participation in this ISO TC is organized through the U.S. Technical Advisory Group for ISO/TC 194, administered by the Association for the Advancement of Medical Instrumentation (AAMI) on behalf of the American National Standards Institute (ANSI). The U.S. made a considerable contribution to this International Standard.

AAMI encourages its committees to harmonize their work with International Standards in the area of biological evaluation of medical devices as much as possible in order to help reduce unnecessary repetition of testing. Upon review of ISO 10993-1, the AAMI Biological Evaluation Committee and the AAMI Systematic Approach to Biological Evaluation Working Group proposed the adoption of 10993-1:2003 verbatim as a revision of ANSI/AAMI/ISO 10993-1:1997.

This edition of ISO 10993-1 has increased the number of biological evaluation tests that need to be considered for external communicating devices and implant devices.

AAMI and ANSI procedures require that American National Standards be reviewed and, if necessary, revised within five years to confirm currency or reflect technological advances that have occurred since publication, as appropriate.

AAMI (and ANSI) have adopted other ISO standards. See the Glossary of Equivalent Standards for a list of ISO standards adopted by AAMI, which gives the corresponding U.S. designation and the level of equivalency with the ISO standard.

The concepts incorporated in this standard should not be considered inflexible or static. This standard, like any other, must be reviewed and updated periodically to assimilate progressive technological developments. To remain relevant, it must be modified as technological advances are made and new data comes to light.

Suggestions for improving this standard are invited. Comments and suggested revisions should be sent to Standards Department, AAMI, 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795.

NOTE—Beginning with the ISO foreword on page x, this American National Standard is identical to ISO 10993-1:2003.

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 10993-1 was prepared by Technical Committee ISO/TC 194, *Biological evaluation of medical devices*.

This third edition cancels and replaces the second edition (ISO 10993-1:1997), of which it constitutes a minor revision.

ISO 10993 consists of the following parts, under the general title *Biological evaluation of medical devices*:

- *Part 1: Evaluation and testing*
- *Part 2: Animal welfare requirements*
- *Part 3: Tests for genotoxicity, carcinogenicity, and reproductive toxicity*
- *Part 4: Selection of tests for interactions with blood*
- *Part 5: Tests for in vitro cytotoxicity*
- *Part 6: Tests for local effects after implantation*
- *Part 7: Ethylene oxide sterilization residuals*
- *Part 8: Selection and qualification of reference materials for biological tests*
- *Part 9: Framework for identification and quantification of potential degradation products*
- *Part 10: Tests for irritation and delayed-type hypersensitivity*
- *Part 11: Tests for systemic toxicity*
- *Part 12: Sample preparation and reference materials*
- *Part 13: Identification and quantification of degradation products from polymeric medical devices*
- *Part 14: Identification and quantification of degradation products from ceramics*
- *Part 15: Identification and quantification of degradation products from metals and alloys*
- *Part 16: Toxicokinetic study design for degradation products and leachables*
- *Part 17: Establishment of allowable limits for leachable substances*
- *Part 18: Chemical characterization of materials*

Future parts will deal with other relevant aspects of biological testing.

Introduction

This part of ISO 10993 is a combination/harmonization of numerous international and national standards and guidelines concerning the biological evaluation of medical devices. It is intended to be the overall guidance document for the selection of tests enabling evaluation of biological responses relevant to the safety of medical devices and materials.

The role of this part of ISO 10993 is to serve as a framework in which to plan such a biological evaluation which minimizes the number and exposure of test animals.

The protection of humans is the primary goal of ISO 10993.

The appropriate selection and interpretation of biological evaluation tests requires an understanding of the rationale behind such testing. An informative rationale for the use of this part of ISO 10993 is provided in Annex A. Annex B contains a flow chart to aid in the systematic approach to the biological evaluation of medical devices. A bibliography is given at the end of the text.

Biological evaluation of medical devices—

Part 1: Evaluation and testing

1 Scope

This part of ISO 10993 describes

- a) the general principles governing the biological evaluation of medical devices;
- b) the categorization of devices based on the nature and duration of their contact with the body;
- c) the selection of appropriate tests.

This part of ISO 10993 does not cover testing of materials and devices that do not come into direct or indirect contact with the patient's body, nor does it cover biological hazards arising from any mechanical failure.

NOTE—Other parts of ISO 10993 cover specific tests (see also the rationale in A.2).

2 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

2.1 medical device: Any instrument, apparatus, appliance, material, or other article, including software, whether used alone or in combination, intended by the manufacturer to be used for human beings solely or principally for the purpose of:

- diagnosis, prevention, monitoring, treatment, or alleviation of disease;
- diagnosis, monitoring, treatment, alleviation of, or compensation for an injury or handicap;
- investigation, replacement, or modification of the anatomy or of a physiological process;
- control of conception;

and which does not achieve its principal intended action in or on the human body by pharmacological, immunological, or metabolic means, but which may be assisted in its function by such means.

NOTE 1—Devices are different from drugs, and their biological evaluation requires a different approach.

NOTE 2—Use of the term “medical device” includes dental devices.

2.2 material: Any synthetic or natural polymer, metal, alloy, ceramic, or other nonviable substance, including tissue rendered nonviable, used as a medical device, or any part thereof.

2.3 final product: Medical device in its “as-used” state.

3 General principles applying to biological evaluation of medical devices

3.1 The selection and evaluation of any material or device intended for use in humans requires a structured program of assessment.

In the design process, an informed decision shall be made and documented that weighs the advantages/disadvantages of the various choices of material and test procedure. To give assurance that the final product will perform as intended and be safe for human use, the program shall include a biological evaluation.

The biological evaluation shall be planned, carried out, and documented by knowledgeable and experienced individuals capable of making informed decisions based on the advantages and disadvantages of the various materials and test procedures available.

3.2 In the selection of materials to be used in device manufacture, the first consideration should be fitness for purpose with regard to characteristics and properties of the material, which include chemical, toxicological, physical, electrical, morphological, and mechanical properties.

3.3 The following should be considered for their relevance to the overall biological evaluation of the device:

- a) the material(s) of manufacture;
- b) intended additives, process contaminants, and residues;
- c) leachable substances;
- d) degradation products;
- e) other components and their interactions in the final product;
- f) the properties and characteristics of the final product.

NOTE—If appropriate, identification and quantification of extractable chemical entities of the final product should precede biological evaluation (see ISO 10993-9).

3.4 Tests to be used in biological evaluation, and the interpretation of the results of such tests, should take into account the chemical composition of the materials, including the conditions of exposure and the nature, degree, frequency, and duration of exposure of the device or its constituents to the body. By following these principles, devices can be categorized to facilitate the selection of appropriate tests (see Clause 4). This part of ISO 10993 is concerned with the tests to be carried out on materials and/or the final product.

The range of potential biological hazards is wide and may include:

- a) short-term effects (e.g., acute toxicity, irritation to the skin, eye and mucosal surfaces, sensitization, hemolysis, and thrombogenicity);
- b) long-term or specific toxic effects (e.g., subchronic and chronic toxic effects, sensitization, genotoxicity, carcinogenicity (tumorigenicity), and effects on reproduction including teratogenicity).

3.5 All potential biological hazards should be considered for every material and final product, but this does not imply that testing for all potential hazards will be necessary or practical (see Clause 6).

3.6 Any *in vitro* or *in vivo* tests shall be based on end-use applications and appropriate good laboratory practice followed by evaluation by competent informed persons. Whenever possible, *in vitro* screening should be carried out before *in vivo* tests are commenced. Test data, complete to the extent that an independent analysis could be made, shall be retained (see A.2, "Subclause 3.6").

3.7 The materials or final product shall be considered for biological re-evaluation if any of the following occurs:

- a) any change in the source or in the specification of the materials used in the manufacture of the product;
- b) any change in the formulation, processing, primary packaging, or sterilization of the product;
- c) any change in the final product during storage;
- d) any change in the intended use of the product;
- e) any evidence that the product may produce adverse effects when used in humans.

3.8 The biological evaluation performed in accordance with this part of ISO 10993 should be considered in conjunction with the nature and mobility of the ingredients in the materials used to manufacture the device and other information, other non-clinical tests, clinical studies, and post-market experience for an overall assessment (see A.2, "Subclause 3.8").

4 Categorization of medical devices

4.1 General

Following the general principles laid down in Clause 3, medical devices can be categorized to facilitate the selection of appropriate tests.

The testing of any device that does not fall into one of the categories described should follow the general principles contained in this part of ISO 10993. Certain devices may fall into more than one category, in which case testing appropriate to each category should be considered.

Medical devices shall be categorized according to the nature and duration of body contact as described in 4.2 and 4.3.

4.2 Categorization by nature of body contact

4.2.1 Non-contact devices

Medical devices that do not contact the patient's body directly or indirectly are not included in the scope of ISO 10993.

4.2.2 Surface-contacting devices

These include medical devices in contact with the following surfaces:

- a) **skin:** devices that contact intact skin surfaces only; examples include electrodes, external prostheses, fixation tapes, compression bandages, and monitors of various types;
- b) **mucosal membranes:** devices that contact intact mucosal membranes; examples include contact lenses, urinary catheters, intravaginal and intrainestinal devices (stomach tubes, sigmoidoscopes, colonoscopes, gastroscopes), endotracheal tubes, bronchoscopes, dental prostheses, orthodontic devices, and intrauterine devices;
- c) **breached or compromised surfaces:** devices that contact breached or otherwise compromised body surfaces; examples include dressings, healing devices, and occlusive patches for ulcers, burns, and granulation tissue.

4.2.3 External communicating devices

These include medical devices in contact with the following application sites:

- a) **blood path, indirect:** devices that contact the blood path at one point and serve as a conduit for entry into the vascular system; examples include solution administration sets, extension sets, transfer sets, and blood administration sets;
- b) **tissue/bone/dentin:** devices that contact tissue, bone, or pulp/dentin systems; examples include laparoscopes, arthroscopes, draining systems, dental cements, dental filling materials, and skin staples;
- c) **circulating blood:** devices that contact circulating blood; examples include intravascular catheters, temporary pacemaker electrodes, oxygenators, extracorporeal oxygenator tubing and accessories, dialyzers, dialysis tubing and accessories, hemoadsorbents, and immunoabsorbents.

4.2.4 Implant devices

These include medical devices in contact with the following application sites:

- a) **tissue/bone:**
 - 1) devices principally contacting bone; examples include orthopedic pins, plates, replacement joints, bone prostheses, bone cements, and intraosseous devices;
 - 2) devices principally contacting tissue and tissue fluid; examples include pacemakers, drug supply devices, neuromuscular sensors and stimulators, replacement tendons, breast implants, artificial larynxes, subperiosteal implants, and ligation clips;
- b) **blood:** devices principally contacting blood; examples include pacemaker electrodes, artificial arteriovenous fistulae, heart valves, vascular grafts, internal drug-delivery catheters, and ventricular assist devices.

4.3 Categorization by duration of contact

Medical devices shall be categorized according to the duration of contact as follows:

- a) **limited exposure (A):** devices whose single or multiple use or contact is likely to be up to 24 h;
- b) **prolonged exposure (B):** devices whose single, multiple, or long-term use or contact is likely to exceed 24 h but not 30 days;

- c) **permanent contact (C)**: devices whose single, multiple, or long-term use or contact exceeds 30 days.

If a material or device may be placed in more than one duration category, the more rigorous testing requirements shall apply. With multiple exposures to the device, the decision into which category a device is placed should take into account the potential cumulative effect, bearing in mind the period of time over which these exposures occur.

5 Testing

5.1 General

In addition to the general principles laid down in Clause 3, the following shall apply to biological testing of medical devices.

- a) Testing shall be performed on the final product, or on representative samples taken from the final product or from the materials processed in the same manner as the final product.
- b) The choice of test procedures shall take into account:
 - 1) the nature, degree, duration, frequency, and conditions of exposure to or contact of humans with the device in the normal intended use;
 - 2) the chemical and physical nature of the final product;
 - 3) the toxicological activity of the chemical elements or compounds in the formulation of the final product;
 - 4) that certain tests (e.g., those designed to assess systemic effects) may not be applicable where the presence of leachable materials has been excluded, or where leachables have a known and acceptable toxicity profile;
 - 5) the relationship of device surface area to recipient body size;
 - 6) the existing information based on the literature, experience, and non-clinical tests;
 - 7) that the protection of humans is the primary goal of this document, a secondary goal being to ensure animal welfare and to minimize the number and exposure of test animals.
- c) If extracts of the devices are prepared, the solvents and conditions of extraction used shall be appropriate to the nature and use of the final product.
- d) Positive and negative controls shall be used where appropriate.
- e) Test results cannot ensure freedom from potential biological hazard; thus, biological investigations shall be followed by careful observations for unexpected adverse reactions or events in humans during clinical use of the device.

A bibliography of International Standards and guidelines on biological-response test methods is given at the end of the text.

5.2 Initial evaluation tests

5.2.1 General

The tests that shall be considered for initial biological response are given in 5.2.2 to 5.2.10.

5.2.2 Cytotoxicity

With the use of cell culture techniques, these tests determine the lysis of cells (cell death), the inhibition of cell growth, and other effects on cells caused by medical devices, materials, and/or their extracts. Cytotoxicity tests are described in ISO 10993-5.

5.2.3 Sensitization

These tests estimate, using an appropriate model, the potential of medical devices, materials, and/or their extracts for contact sensitization. These tests are appropriate because exposure or contact to even minute amounts of potential leachables can result in allergic or sensitization reactions. Sensitization tests are described in ISO 10993-10.

5.2.4 Irritation

These tests estimate the irritation potential of medical devices, materials, and/or their extracts, using appropriate sites for implant tissue such as skin, eye, and mucous membrane in a suitable model. The test(s) performed should be appropriate for the route (skin, eye, mucosa) and duration of exposure or contact to determine irritant effects of devices, materials, and potential leachables. Irritation tests are described in ISO 10993-10.

5.2.5 Intracutaneous reactivity

These tests assess the localized reaction of tissue to medical device extracts. These tests are applicable where determination of irritation by dermal or mucosal tests are inappropriate (e.g., medical devices having access to the blood path). These tests may also be useful where extractables are hydrophobic. Intracutaneous reactivity tests are described in ISO 10993-10.

5.2.6 Systemic toxicity (acute toxicity)

These tests estimate the potential harmful effects of either single or multiple exposures, during a period of less than 24 h, to medical devices, materials, and/or their extracts in an animal model. These tests are appropriate where contact allows potential absorption of toxic leachables and degradation products.

Pyrogenicity tests are included to detect material-mediated pyrogenic reactions of extracts of medical devices or materials. No single test can differentiate pyrogenic reactions that are material-mediated from those due to endotoxin contamination. Systemic toxicity tests are described in ISO 10993-11.

Immunotoxicity tests should be considered only for devices where data from other sources is suggestive of immunotoxicological effects.

Systemic toxicity tests may be included in subacute and subchronic toxicity test protocols and implantation test protocols.

5.2.7 Subacute and subchronic toxicity

These tests determine the effects of either single or multiple exposures or contact to medical devices, materials, and/or their extracts for a period of not less than 24 h but not greater than 10 % of the total life span of the test animal (e.g., up to 90 days in rats). These tests may be waived for materials with chronic toxicity data. The reason for waiving of the tests should be included in the final report. These tests should be appropriate for the route and duration of contact. Subchronic toxicity tests are described in ISO 10993-11.

5.2.8 Genotoxicity

These tests use mammalian or non-mammalian cell culture or other techniques to determine gene mutations, changes in chromosome structure and number, and other DNA or gene toxicities caused by medical devices, materials, and/or their extracts. Genotoxicity tests are described in ISO 10993-3.

5.2.9 Implantation

These tests assess the local pathological effects on living tissue, at both the gross level and microscopic level, of a sample of a material or final product that is surgically implanted or placed in an implant site or in a tissue appropriate to the intended application (e.g., special dental usage tests). These tests should be appropriate for the route and duration of contact. For a material, these tests are equivalent to subchronic toxicity tests if systemic effects are also investigated. Implantation tests are described in ISO 10993-6.

Implantation test protocols may be expanded to include systemic toxicity tests, subacute and subchronic toxicity tests, and chronic toxicity tests.

5.2.10 Hemocompatibility

These tests evaluate, using an appropriate model or system, the effects of blood-contacting medical devices or materials on blood or blood components. Specific hemocompatibility tests may also be designed to simulate the geometry, contact conditions, and flow dynamics of the device or material during clinical applications.

Hemolysis tests determine the degree of red blood cell lysis and the release of hemoglobin caused by medical devices, materials, and/or their extracts *in vitro*. Hemocompatibility tests are described in ISO 10993-4.

5.3 Supplementary evaluation tests

5.3.1 General

The supplementary biological evaluation tests that shall be considered are given in 5.3.2 to 5.3.5.

5.3.2 Chronic toxicity

These tests determine the effects of either single or multiple exposures to medical devices, materials, and/or their extracts during at least 10 % of the life span of the test animal (e.g., more than 90 days in rats). These tests should be appropriate for the route and duration of exposure or contact. Chronic toxicity tests are described in ISO 10993-11.

Chronic toxicity tests may be included in subacute and subchronic toxicity test protocols and implantation test protocols.

5.3.3 Carcinogenicity

These tests determine the tumorigenic potential of medical devices, materials, and/or their extracts from either single or multiple exposures or contacts during the major portion of the life span of the test animal. These tests may be designed in order to examine both chronic toxicity and tumorigenicity in a single experimental study. Carcinogenicity tests should be conducted only if there is suggestive data from other sources. These tests should be appropriate for the route and duration of exposure or contact. Carcinogenicity tests are described in ISO 10993-3.

5.3.4 Reproductive and developmental toxicity

These tests evaluate the potential effects of medical devices, materials, and/or their extracts on reproductive function, embryonic development (teratogenicity), and prenatal and early postnatal development. Reproductive/developmental toxicity tests or bioassays should only be conducted when the device has potential impact on the reproductive potential of the subject. The application site of the device should be considered. Reproductive and developmental toxicity tests are described in ISO 10993-3.

5.3.5 Biodegradation

Where the potential for resorption and/or degradation exists, corresponding tests may determine the processes of absorption, distribution, biotransformation, and elimination of leachables and degradation products of medical devices, materials, and/or their extracts. Biodegradation tests are described in ISO 10993-9.

6 Selection of biological evaluation tests

Evaluation may include both a study of relevant experience and actual testing. Such an evaluation may result in the conclusion that no testing is needed if the material has a demonstrable history of use in a specified role that is equivalent to that of the device under design.

Table 1 identifies the initial evaluation tests that shall be considered for each device and duration category. Table 2 identifies the supplementary evaluation tests that shall be considered for each device and duration category.

Due to the diversity of medical devices, it is recognized that not all tests identified in a category will be necessary or practical for any given device. It is indispensable for testing that each device be considered on its own merits: additional tests not indicated in the table may be necessary.

The tests considered and the rationale for selection and/or waiving of tests shall be recorded.

7 Assurance of test methods

7.1 Test method assurance

The test methods used in the biological evaluation shall be sensitive, precise and accurate. The test results should be reproducible (interlaboratory) as well as repeatable (intralaboratory).

7.2 Continued assurance

The assurance that a material is initially acceptable for its intended use in a medical device, and of its continued acceptability in the long term, is an aspect of a quality management system (see A.2, "Subclause 7.2").

NOTE—ISO 9001 specifies the requirements for such quality management systems. ISO 9004 provides more detailed guidance for designing and manufacturing products.

Table 1—Initial evaluation tests for consideration

Medical device categorization by			Biological effect							
Nature of body contact (see 4.2)		Contact duration (see 4.3) A — Limited (< 24 h) B — Prolonged (24 h to 30 days) C — Permanent (> 30 days)	Cytotoxicity	Sensitization	Irritation or intracutaneous reactivity	Systemic toxicity (acute)	Subacute and subchronic toxicity	Genotoxicity	Implantation	Hemocompatibility
Category	Contact									
Surface device	Skin	A	x	x	x					
		B	x	x	x					
		C	x	x	x					
	Mucosal membrane	A	x	x	x					
		B	x	x	x					
		C	x	x	x		x	x		
	Breached or compromised surface	A	x	x	x					
		B	x	x	x					
		C	x	x	x		x	x		
External communicating device	Blood path, indirect	A	x	x	x	x				x
		B	x	x	x	x				x
		C	x	x		x	x	x		x
	Tissue/bone/dentin	A	x	x	x					
		B	x	x	x	x	x	x	x	
		C	x	x	x	x	x	x	x	
	Circulating blood	A	x	x	x	x				x
		B	x	x	x	x	x	x	x	x
		C	x	x	x	x	x	x	x	x
Implant device	Tissue/ bone	A	x	x	x					
		B	x	x	x	x	x	x	x	
		C	x	x	x	x	x	x	x	
	Blood	A	x	x	x	x	x		x	x
		B	x	x	x	x	x	x	x	x
		C	x	x	x	x	x	x	x	x
NOTE—This table is a framework for the development of an assessment program and is not a checklist (see Clause 6).										

Table 2—Supplementary evaluation tests for consideration

Medical device categorization by			Biological effect			
Nature of body contact (see 4.2)		Contact duration (see 4.3) A — Limited (< 24 h) B — Prolonged (24 h to 30 days) C — Permanent (> 30 days)	Chronic toxicity	Carcinogenicity	Reproductive/developmental	Biodegradation
Category	Contact					
Surface device	Skin	A				
		B				
		C				
	Mucosal membrane	A				
		B				
		C				
	Breached or compromised surface	A				
		B				
		C				
External communicating device	Blood path, indirect	A				
		B				
		C	x	x		
	Tissue/ bone/dentin	A				
		B				
		C	x	x		
	Circulating blood	A				
		B				
		C	x	x		
Implant device	Tissue/ bone	A				
		B				
		C	x	x		
	Blood	A				
		B				
		C	x	x		

NOTE—This table is a framework for the development of an assessment program and is not a checklist (see Clause 6).

Annex A

(informative)

Rationale

A.1 General

This part of ISO 10993 is concerned with the safety-in-use of medical devices and materials. It is intended to assess the biological response of devices and materials as part of the overall evaluation and development of devices and materials. Like other current work on this subject, it addresses the determination of the effects of devices and materials on tissue in a general way, rather than for specific individual applications. This part of ISO 10993 thus classifies medical devices into broad categories and indicates, in matrices, the biological tests that are thought to be relevant for consideration for each device category.

Expanded test protocols may combine initial evaluation tests. Examples could be sensitization, irritation, and intracutaneous reactivity tests in a single, expanded protocol; or systemic toxicity, subacute and subchronic toxicity, chronic toxicity, and implantation tests in a single, expanded protocol.

The range of biological hazards is wide. The tissue interaction of a material cannot be considered in isolation from the overall device design. The best material with respect to tissue interaction may result in a less functional device, tissue interaction being only one characteristic of a material. Where the material is intended to interact with tissue in order for the device to perform its function, evaluation takes on dimensions not generally addressed in standards and guidelines to date.

Biological reactions that are adverse for a material in one application may not be adverse for the use of the material in a different application. Biological testing relies upon animal models and a material cannot, therefore, be conclusively shown to have the same tissue reactions in humans. In addition, differences between humans suggest that some patients may have adverse reactions even to well-established materials.

Currently, biological testing relies on animal models. However, as scientific knowledge advances our understanding of basic mechanisms, preference should be given to *in vitro* models in situations where scientific evidence yields equally relevant information.

For medical devices and materials, the application of a rigid set of test methods and pass/fail criteria might result in either an unnecessary restriction, or a false sense of security, in their use. Where a particular application warrants, experts in the product or application area involved may choose to establish specific tests and criteria specified in a product-specific vertical standard.

This part of ISO 10993 is not, therefore, intended to be a set of definitive statements to be followed by individuals not qualified by training and experience; it should be applied with interpretation and judgment by the appropriate professionals qualified by training and experience, taking into consideration the factors relevant to the device/material, its intended use, and the current knowledge of the device/material provided by scientific literature and previous clinical experience.

A.2 Rationale for specific clauses

The following are rationale for specific clauses in this part of ISO 10993, with clause numbers parallel to those in the body of the document.

Clause 1: It is worth acknowledging that there are important material characteristics other than biological ones that should be taken into account in the overall design of the device.

Subclause 3.6: Evaluation may include both a study of relevant experience and actual testing. Such an evaluation may result in the conclusion that no testing is needed if the material has a demonstrable history of use in a specific role that is the same as that of the device under design.


Evaluation should consider intended and unintended interactions between the material and tissues.

Subclause 3.8: This clause is intended to avoid the need for redundant experiments when information about the material and/or device is available from other sources.

Subclause 7.2: The selection and evaluation of materials that will come into contact with tissue require a structured process so that the materials incorporated in the final design contribute to the overall biological evaluation assurance of the design.

Annex B (informative)

Flow chart to aid in ensuring a systemic approach to biological evaluation of medical devices



^a Refers to clause/subclause in main text.

**Figure B.1—Flow chart to aid in ensuring a systemic approach
to biological evaluation of medical devices**

Bibliography

International Organization for Standardization (ISO)

- [1] ISO 7405:1997, *Dentistry—Preclinical evaluation of biocompatibility of medical devices used in dentistry—Test methods for dental materials*
- [2] ISO 9000:2000, *Quality management systems—Fundamentals and vocabulary*
- [3] ISO 9001:2000, *Quality management systems—Requirements*
- [4] ISO 9004:2000, *Quality management systems—Guidelines for performance improvements*
- [5] ISO 10993-3:2003, *Biological evaluation of medical devices—Part 3: Tests for genotoxicity, carcinogenicity, and reproductive toxicity*
- [6] ISO 10993-4:2002, *Biological evaluation of medical devices—Part 4: Selection of tests for interactions with blood*
- [7] ISO 10993-5:1999, *Biological evaluation of medical devices—Part 5: Tests for in vitro cytotoxicity*
- [8] ISO 10993-6:1994, *Biological evaluation of medical devices—Part 6: Tests for local effects after implantation*
- [9] ISO 10993-9:1999, *Biological evaluation of medical devices—Part 9: Framework for identification and quantification of potential degradation products*
- [10] ISO 10993-10:2002, *Biological evaluation of medical devices—Part 10: Tests for irritation and delayed-type hypersensitivity*
- [11] ISO 10993-11:1993, *Biological evaluation of medical devices—Part 11: Tests for systemic toxicity*
- [12] ISO 13485:2003, *Medical devices—Quality systems—System requirements for regulatory purposes*
- [13] ISO 13488:1996, *Quality systems—Medical devices—Particular requirements for the application of ISO 9002*
- [14] ISO/IEC 17025:1999, *General requirements for the competence of testing and calibration laboratories*

Organization for Economic Cooperation and Development (OECD)

- [15] *Guidelines for the testing of chemicals—Section 4: Health effects*